Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Immunology ; 122(4): 562-70, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17645499

RESUMO

Type I interferons (IFNs), IFN-alpha and IFN-beta, are widely used for treating chronic hepatitis C. Although retrospective studies have suggested that type I IFNs have direct antifibrotic effects, little is known about these mechanisms. The present study was designed to clarify the preventive mechanisms of type I IFNs in the progression of fibrosis for the establishment of a more effective therapy. A murine fibrosis model comprising immunological reactions was induced by the administration of concanavalin A (0.3 mg/body) into mice once a week for 4 weeks. Liver injury and the degree of fibrosis were determined by measuring the serum alanine aminotransferase activities and liver hydroxyproline contents with or without IFN-beta pretreatment. IFN-beta suppressed the hepatocellular injury and increased the hydroxyproline content induced by repeated concanavalin A injections, but had no effect on established fibrosis. Furthermore, IFN-beta reduced the expressions of transforming growth factor-beta, basic fibroblast growth factor, collagen type I A2 and tissue inhibitor of metalloproteinase 1 messenger RNAs, which are related to the progression of liver fibrosis. The IFN-beta reduced the liver injury and fibrosis induced by immunological reactions. These data suggest that type I IFNs suppress the progression of cirrhosis through inhibition of repeated hepatocellular injury and/or factors that promote the liver fibrosis induced by hepatitis virus infection.


Assuntos
Interferon Tipo I/uso terapêutico , Cirrose Hepática Experimental/prevenção & controle , Animais , Colágeno/biossíntese , Colágeno/genética , Colágeno Tipo I , Concanavalina A , Citocinas/biossíntese , Citocinas/genética , Progressão da Doença , Avaliação Pré-Clínica de Medicamentos , Feminino , Regulação da Expressão Gênica/efeitos dos fármacos , Substâncias de Crescimento/biossíntese , Substâncias de Crescimento/genética , Hemostasia/efeitos dos fármacos , Hidroxiprolina/metabolismo , Interferon Tipo I/farmacologia , Fígado/metabolismo , Circulação Hepática/efeitos dos fármacos , Cirrose Hepática Experimental/tratamento farmacológico , Cirrose Hepática Experimental/imunologia , Cirrose Hepática Experimental/patologia , Camundongos , Camundongos Endogâmicos BALB C , Proteínas Recombinantes , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Inibidor Tecidual de Metaloproteinase-1/biossíntese , Inibidor Tecidual de Metaloproteinase-1/genética
2.
Exp Parasitol ; 117(2): 124-32, 2007 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-17574244

RESUMO

Arginine kinase (AK) is a member of a highly conserved family of phosphagen kinases. We determined the cDNA sequence of Toxocara canis AK, cloned it in pMAL plasmid and expressed it in Escherichia coli as a fusion protein with maltose-binding protein. The protein has a theoretical molecular mass of 45,376 Da and an estimated isoelectric point (pI) of 8.38. Alignment of the cDNA-derived amino acid sequence of T. canis AK with other phosphagen kinase sequences showed high amino acid identity with other nematode AKs, and phylogenetic analysis placed it as a distinct branch within a nematode AK cluster. Analysis of the N-terminus sequence of T. canis AK revealed the presence of a signal targeting peptide presumably targeting this protein to cytosol or endoplasmic reticulum (ER). T. canis AK showed high activity for l-arginine. The kinetic constants (K(m) = 0.12 mM, K(cat) = 29.18, and K(d) = 0.23 mM) and V(max) (43.76 micromolPi/min/mg protein) of T. canis recombinant-AK were determined for the forward reaction. It also exhibited a synergism for substrate binding (K(d)(Arg)/K(m)(Arg)=1.96). Comparison of K(cat)/K(m)(Arg) values in various arginine kinases indicates that T. canis AK has a high catalytic efficiency (248.19s(-1)mM(-1)). The present study contains the first description of arginine kinase in a zoonotic nematode. The determination of T. canis AK and its phosphagen biosynthetic pathway, which is completely different from those in mammalian host tissues, suggests this enzyme as a possible novel chemotherapy target for VLM syndrome in humans.


Assuntos
Arginina Quinase/genética , Toxocara canis/enzimologia , Toxocara canis/genética , Sequência de Aminoácidos , Animais , Arginina/química , Arginina/metabolismo , Arginina Quinase/química , Arginina Quinase/classificação , Arginina Quinase/metabolismo , Clonagem Molecular , DNA Complementar/química , Cães , Eletroforese em Gel de Poliacrilamida , Regulação Enzimológica da Expressão Gênica , Imageamento Tridimensional , Ponto Isoelétrico , Cinética , Dados de Sequência Molecular , Peso Molecular , Filogenia , Sinais Direcionadores de Proteínas/genética , RNA de Helmintos/genética , Proteínas Recombinantes/classificação , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Alinhamento de Sequência
3.
Int J Biol Macromol ; 37(1-2): 54-60, 2005 Oct 30.
Artigo em Inglês | MEDLINE | ID: mdl-16188310

RESUMO

The giant tubeworm Riftia pachyptila lives at deep-sea hydrothermal vents along the East Pacific Rise and the Galapagos Rift. The large size and high growth rate of R. pachyptila is supported by an endosymbiotic relationship with a chemosynthetic bacterium. Elucidation of the regulation of energy metabolism of the giant tubeworm remains an interesting problem. The purpose of this study is to determine the cDNA sequence of phosphagen kinase, one of the most important enzymes in energy metabolism, and to characterize its function. Two phosphagen kinase cDNA sequences amplified from the cDNA library of R. pachyptila showed high derived amino acid sequence identity (74%) with those of cytoplasmic taurocyamine kinase (TK) and mitochondrial TK from an annelid Arenicola brasiliensis. The cytoplasmic form of the Riftia recombinant enzyme showed stronger activity for the substrates taurocyamine and also considerable activity for lombricine (21% that of taurocyamine). The mitochondrial form, which was structurally similar to mitochondrial creatine kinase, showed stronger activity for taurocyamine, and a broader activity for various guanidine compounds: glycocyamine (35% that of taurocyamine), lombricine (31%) and arginine (3%). Both forms showed no activity for creatine. The difference in substrate specificities between the cytoplasmic and mitochondrial forms might be attributable to the large difference in the amino acid sequence of the GS region and/or several key amino acid residues for establishing guanidine substrate specificity. Based on these results, we conclude that Riftia contains at least two forms of TK as phosphagen kinase. We also report the kinetic parameters, Km and kcat, of Arenicola and Riftia TKs for the first time. The Km values for taurocyamine of Arenicola and Riftia TKs ranged from 0.9 to 4.0 mM and appear to be comparable to those of other annelid-specific enzymes, lombricine kinase and glycocyamine kinase, but are significantly lower than those of Neanthes cytoplasmic and mitochondrial creatine kinases. Comparison of kcat/Km value in various annelid phosphagen kinases indicates that Arenicola mitochondrial TK has the highest catalytic efficiency (16.2 s-1 mM-1). In Arenicola TKs, the mitochondrial form has seven-fold higher efficiency than the cytoplasmic form.


Assuntos
Citoplasma/metabolismo , Mitocôndrias/metabolismo , Fosfotransferases (Aceptor do Grupo Nitrogenado)/química , Fosfotransferases (Aceptor do Grupo Nitrogenado)/genética , Sequência de Aminoácidos , Animais , Anelídeos , Arginina/química , Catálise , Clonagem Molecular , Creatina/química , DNA Complementar/metabolismo , Evolução Molecular , Biblioteca Gênica , Glicina/análogos & derivados , Glicina/química , Helmintos , Cinética , Dados de Sequência Molecular , Fosfotransferases (Aceptor do Grupo Nitrogenado)/biossíntese , Filogenia , Isoformas de Proteínas , Proteínas Recombinantes/química , Homologia de Sequência de Aminoácidos , Serina/análogos & derivados , Serina/química , Temperatura
4.
Gene ; 298(1): 21-7, 2002 Sep 18.
Artigo em Inglês | MEDLINE | ID: mdl-12406572

RESUMO

Calcyphosine is an EF-hand Ca(2+)-binding protein, which was first isolated from the canine thyroid. It is phosphorylated in a cyclic AMP (cAMP)-dependent manner; then it is thought to be implicated in the cross-signaling between the cAMP and calcium-phosphatidylinositol cascades. Here, we isolated the DNA complementary to RNA (cDNA) of an EF-hand Ca(2+)-binding protein from the sponge, Halichondria okadai and determined its genomic structure. The deduced sequence of the sponge Ca(2+)-binding protein showed significant similarity (about 40% identity) with those of mammal calcyphosines, and the intron positions were well conserved between the sponge and human calcyphosine genes. We considered that the isolated cDNA was that of sponge calcyphosine, and that sponge and mammalian calcyphosines evolved from a common ancestor gene. Recent cDNA projects have revealed that a calcyphosine cDNA is also expressed by human, mouse, and the ascidia. These cDNAs have more than 60% identity with sponge calcyphosine and each other, and all are composed of 208 amino acid residues. On the constructed phylogenetic trees, calcyphosines are essentially divided into two groups, types-I and -II calcyphosines. Type-I calcyphosine may be specific to mammals, and type-II is widely distributed among metazoan species. This suggests that type-II calcyphosine is a rather ancient gene with some essential function.


Assuntos
Proteínas de Ligação ao Cálcio/genética , Poríferos/genética , Sequência de Aminoácidos , Animais , Sequência de Bases , DNA/química , DNA/genética , DNA Complementar/química , DNA Complementar/genética , Evolução Molecular , Éxons , Genes/genética , Íntrons , Dados de Sequência Molecular , Filogenia , Alinhamento de Sequência , Análise de Sequência de DNA , Homologia de Sequência de Aminoácidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA